C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.87% | 7.19% | 0.52% | 8.77% | 50.68% |
| Total Depreciation and Amortization | 37.28% | 1.79% | 11.63% | -1.12% | -2.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.06% | -0.61% | 26.42% | -2.54% | -7.06% |
| Change in Net Operating Assets | 23.50% | -511.62% | 118.13% | 33.31% | -37.41% |
| Cash from Operations | -142.40% | -83.71% | 25.31% | 21.41% | 73.82% |
| Capital Expenditure | 6.09% | -- | 102.55% | 102.17% | 45.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 439.79% | 154.55% | -57.43% | -99.74% | -174.20% |
| Cash from Investing | 432.49% | 154.55% | -57.21% | -99.72% | -177.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -99.81% | -- | 6,650.00% |
| Repurchase of Common Stock | -- | -42.20% | -- | -431.25% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 29.76% | 200.00% | 12.93% | -100.00% |
| Cash from Financing | -100.00% | -100.13% | -99.81% | 197.70% | 118.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 262.37% | 88.61% | -106.33% | -182.79% | -260.07% |